Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Occupational asthma: Pathogenesis

INTRODUCTION

The label "asthma in the workplace" encompasses several entities: (1) asthma exacerbated at work by various environmental conditions; (2) occupational asthma; and (3) variants (eg, eosinophilic bronchitis) [1]. Occupational asthma is a disease characterized by variable airflow limitation, airway hyperresponsiveness, and inflammation resulting from an inciting agent only found in the workplace [2].

The pathogenesis and pathology of occupational asthma will be reviewed here. Issues related to other aspects of occupational asthma are discussed separately. (See "Occupational asthma: Definitions, epidemiology, causes, and risk factors" and "Occupational asthma: Clinical features and diagnosis" and "Reactive airways dysfunction syndrome and irritant-induced asthma".)

TYPES

Two main types of occupational asthma have been recognized [1,3]:

Immunologically mediated. This type includes IgE and nonIgE-mediated responses following chronic exposure to high or low molecular weight agents.

Nonimmunologic, irritant mediated. This type includes reactive airways dysfunction syndrome (RADS) caused by a single high level exposure to an irritant and also chronic lower level exposure. (See "Reactive airways dysfunction syndrome and irritant-induced asthma".)

            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Jan 29, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Bernstein, IL, Chan-Yeung, M, Malo, JL, Berstein, DI. Asthma in the workplace, 3rd, Taylor and Francis, New York 2006.
  2. Malo JL, Chan-Yeung M, Bernstein DI. Asthma in the Workplace, 4th ed, CRC Press, Boca Raton, FL 2013.
  3. Maestrelli P, Boschetto P, Fabbri LM, Mapp CE. Mechanisms of occupational asthma. J Allergy Clin Immunol 2009; 123:531.
  4. Boulet LP, Boutet M, Laviolette M, et al. Airway inflammation after removal from the causal agent in occupational asthma due to high and low molecular weight agents. Eur Respir J 1994; 7:1567.
  5. Bentley, AM, Maestrelli, et al. Immunochemistry of the bronchial mucosa in occupational, intrinsic and extrinsic asthma. J Allergy Clin Immunol 1991; 87:246.
  6. Frew AJ, Chan H, Lam S, Chan-Yeung M. Bronchial inflammation in occupational asthma due to western red cedar. Am J Respir Crit Care Med 1995; 151:340.
  7. Zhu Z, Zheng T, Homer RJ, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004; 304:1678.
  8. Bergeron C, Boulet LP. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 2006; 129:1068.
  9. Saetta M, Di Stefano A, Maestrelli P, et al. Airway mucosal inflammation in occupational asthma induced by toluene diisocyanate. Am Rev Respir Dis 1992; 145:160.
  10. Boulet LP, Chakir J, Dubé J, et al. Airway inflammation and structural changes in airway hyper-responsiveness and asthma: an overview. Can Respir J 1998; 5:16.
  11. Maghni K, Lemière C, Ghezzo H, et al. Airway inflammation after cessation of exposure to agents causing occupational asthma. Am J Respir Crit Care Med 2004; 169:367.
  12. Sumi Y, Foley S, Daigle S, et al. Structural changes and airway remodelling in occupational asthma at a mean interval of 14 years after cessation of exposure. Clin Exp Allergy 2007; 37:1781.
  13. Regal JF. Immunologic effector mechanisms in animal models of occupational asthma. J Immunotoxicol 2004; 1:25.
  14. Lemière C, Malo JL, Boutet M. Reactive airways dysfunction syndrome due to chlorine: sequential bronchial biopsies and functional assessment. Eur Respir J 1997; 10:241.
  15. Demnati R, Fraser R, Ghezzo H, et al. Time-course of functional and pathological changes after a single high acute inhalation of chlorine in rats. Eur Respir J 1998; 11:922.
  16. Martin JG, Campbell HR, Iijima H, et al. Chlorine-induced injury to the airways in mice. Am J Respir Crit Care Med 2003; 168:568.
  17. Chang-Yeung M, Lam S, Kennedy SM, Frew AJ. Persistent asthma after repeated exposure to high concentrations of gases in pulpmills. Am J Respir Crit Care Med 1994; 149:1676.
  18. Malo JL, L'archevêque J, Castellanos L, et al. Long-term outcomes of acute irritant-induced asthma. Am J Respir Crit Care Med 2009; 179:923.
  19. Takeda N, Maghni K, Daigle S, et al. Long-term pathologic consequences of acute irritant-induced asthma. J Allergy Clin Immunol 2009; 124:975.
  20. Newman-Taylor, AJ, Yucesov, B. Genetics and Occupational Asthma. In: Asthma in the Workplace, 3rd, Taylor and Francis, New York 2006. p.87.
  21. Piirilä P, Wikman H, Luukkonen R, et al. Glutathione S-transferase genotypes and allergic responses to diisocyanate exposure. Pharmacogenetics 2001; 11:437.
  22. Mapp CE, Fryer AA, De Marzo N, et al. Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates. J Allergy Clin Immunol 2002; 109:867.
  23. Lummus ZL, Wisnewski AV, Bernstein DI. Pathogenesis and disease mechanisms of occupational asthma. Immunol Allergy Clin North Am 2011; 31:699.
  24. Jones MG, Floyd A, Nouri-Aria KT, et al. Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol 2006; 117:663.
  25. Sjåheim TB, Bjørtuft Ø, Drabløs PA, et al. Increased bronchial density of CD25+Foxp3+ regulatory T cells in occupational asthma: relationship to current smoking. Scand J Immunol 2013; 77:398.
  26. Redlich CA, Herrick CA. Lung/skin connections in occupational lung disease. Curr Opin Allergy Clin Immunol 2008; 8:115.
  27. Pepys J. New tests to assess lung function. inhalation challenge tests in asthma. N Engl J Med 1975; 293:758.
  28. Perrin B, Cartier A, Ghezzo H, et al. Reassessment of the temporal patterns of bronchial obstruction after exposure to occupational sensitizing agents. J Allergy Clin Immunol 1991; 87:630.
  29. Wiszniewska M, Nowakowska-Świrta E, Pałczyński C, Walusiak-Skorupa J. Diagnosing of bakers' respiratory allergy: is specific inhalation challenge test essential? Allergy Asthma Proc 2011; 32:111.
  30. Karol MH, Alarie Y. Antigens which detect IgE antibodies in workers sensitive to toluene diisocyanate. Clin Allergy 1980; 10:101.
  31. Wisnewski AV, Jones M. Pro/Con debate: Is occupational asthma induced by isocyanates an immunoglobulin E-mediated disease? Clin Exp Allergy 2010; 40:1155.
  32. Wisnewski, A, Redlich, CA, Mapp, CE, Bernstein, DI. Polyisocyanates and their Prepolymers. In: Asthma in the workplace, 3rd, Bernstein, IL, Chan-Yeung, M, Malo, JL, Bernstein, DI (Eds), Taylor and Francis, New York 2006. p.481.
  33. Tee RD, Cullinan P, Welch J, et al. Specific IgE to isocyanates: a useful diagnostic role in occupational asthma. J Allergy Clin Immunol 1998; 101:709.
  34. Park HS, Kim HY, Lee SK, et al. Diverse profiles of specific IgE response to toluene diisocyanate (TDI)-human serum albumin conjugate in TDI-induced asthma patients. J Korean Med Sci 2001; 16:57.
  35. Wisnewski AV, Lemus R, Karol MH, Redlich CA. Isocyanate-conjugated human lung epithelial cell proteins: A link between exposure and asthma? J Allergy Clin Immunol 1999; 104:341.
  36. Ye YM, Kang YM, Kim SH, et al. Probable role of Beta 2-adrenergic receptor gene haplotype in toluene diisocyanate-induced asthma. Allergy Asthma Immunol Res 2010; 2:260.
  37. Agius RM. Why are some low-molecular-weight agents asthmagenic. Occup Med 2000; 15:369.
  38. Jarvis J, Seed MJ, Elton R, et al. Relationship between chemical structure and the occupational asthma hazard of low molecular weight organic compounds. Occup Environ Med 2005; 62:243.
  39. Frew A, Chan H, Dryden P, et al. Immunologic studies of the mechanisms of occupational asthma caused by western red cedar. J Allergy Clin Immunol 1993; 92:466.
  40. Tse KS, Chan H, Chan-Yeung M. Specific IgE antibodies in workers with occupational asthma due to western red cedar. Clin Allergy 1982; 12:249.
  41. Bernstein DI, Cartier A, Côté J, et al. Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma. Am J Respir Crit Care Med 2002; 166:445.
  42. Maestrelli P, Del Prete GF, De Carli M, et al. CD8 T-cell clones producing interleukin-5 and interferon-gamma in bronchial mucosa of patients with asthma induced by toluene diisocyanate. Scand J Work Environ Health 1994; 20:376.
  43. Hur GY, Sheen SS, Kang YM, et al. Histamine release and inflammatory cell infiltration in airway Mucosa in methylene diphenyl diisocyanate (MDI)-induced occupational asthma. J Clin Immunol 2008; 28:571.
  44. Frew A, Chang JH, Chan H, et al. T-lymphocyte responses to plicatic acid-human serum albumin conjugate in occupational asthma caused by western red cedar. J Allergy Clin Immunol 1998; 101:841.
  45. Shirakawa T, Kusaka Y, Fujimura N, et al. Hard metal asthma: cross immunological and respiratory reactivity between cobalt and nickel? Thorax 1990; 45:267.
  46. Finotto S, Fabbri LM, Rado V, et al. Increase in numbers of CD8 positive lymphocytes and eosinophils in peripheral blood of subjects with late asthmatic reactions induced by toluene diisocyanate. Br J Ind Med 1991; 48:116.
  47. Raulf-Heimsoth M, Merget R, Rihs HP, et al. T-cell receptor repertoire expression in workers with occupational asthma due to platinum salt. Eur Respir J 2000; 16:871.
  48. Maestrelli P, Yucesoy B, Park HS, Wisnewski A. Mechanism, Genetics and Pathophysiology. In: Asthma in the workplace, 4th, Malo J, Chan-Yeung M, Bernstein D. (Eds), CRC Press, New York 2013.
  49. Johnson, VJ, Luster, MI. Animal models of occupational asthma: Tools for understanding disease pathogenesis. In: Asthma in the workplace, 3rd, Bernstein, IL, Chan-Yeung, M, Malo, J-L, Bernstein, DL (Eds), Taylor and Francis, New York 2006. p.141.
  50. Kouadio K, Zheng KC, Tuekpe MK, et al. Airway inflammatory and immunological events in a rat model exposed to toluene diisocyanate. Food Chem Toxicol 2005; 43:1281.
  51. Herrick CA, Das J, Xu L, et al. Differential roles for CD4 and CD8 T cells after diisocyanate sensitization: genetic control of TH2-induced lung inflammation. J Allergy Clin Immunol 2003; 111:1087.
  52. Butcher BT, Karr RM, O'Neil CE, et al. Inhalation challenge and pharmacologic studies of toluene diisocyanate (TDI)-sensitive workers. J Allergy Clin Immunol 1979; 64:146.
  53. Leroyer C, Perfetti L, Cartier A, Malo JL. Can reactive airways dysfunction syndrome (RADS) transform into occupational asthma due to "sensitisation" to isocyanates? Thorax 1998; 53:152.
  54. Gautrin, D, Bernstein, IL, Brooks, SM, Henneberger, PK. Reactive Airways Dysfunction Syndrome and Irritant-Induced Asthma. In: Asthma in the Workplace, 3rd, Bernstein, IL, Chan-Yeung, M, Malo, JL, Bernstein, DI (Eds), Taylor and Francis, New York 2006. p.579.
  55. Gautrin D, Boulet LP, Boutet M, et al. Is reactive airways dysfunction syndrome a variant of occupational asthma? J Allergy Clin Immunol 1994; 93:12.
  56. Chan-Yeung M, Giclas PC, Henson PM. Activation of complement by plicatic acid, the chemical compound responsible for asthma due to western red cedar (Thuja plicata). J Allergy Clin Immunol 1980; 65:333.
  57. Chitano P, Di Blasi P, Lucchini RE, et al. The effects of toluene diisocyanate and of capsaicin on human bronchial smooth muscle in vitro. Eur J Pharmacol 1994; 270:167.
  58. Mapp CE, Graf PD, Boniotti A, Nadel JA. Toluene diisocyanate contracts guinea pig bronchial smooth muscle by activating capsaicin-sensitive sensory nerves. J Pharmacol Exp Ther 1991; 256:1082.
  59. Perfetti L, Bramé B, Ferrari M, Moscato G. Occupational asthma (OA) with sensitization to diphenylmethane diisocyanate (MDI) presenting at the onset like a reactive airways dysfunction syndrome (RADS). Am J Ind Med 2003; 44:325.